Regarding Techcyte and Biobase Partnership on LinkedIn
From LinkedIn regarding Techcyte and Biobase partnership
Sam Seymour, CPO and Co-Founder at Biobase:
I started in digital pathology over 6 years ago at Paige (now Tempus AI). Not a lot has changed since then; digital pathology’s adoption problem has always been the ROI math. The companies that are seeing success in the market have found paths to revenue outside of reimbursement incentives for slide digitization (e.g. PathAI and Artera).
Today Biobase and Techcyte announced a partnership that changes the math on digitizing slides: labs on Techcyte Fusion can now selectively commercialize their de-identified pathology data through Biobase’s federated platform. This turns a cost center into a revenue stream, with full opt-in control at the program or case level.
DigitalPathology PathologyAI RealWorldData ComputationalPathology PrecisionMedicine
Techcyte:
Techcyte and Biobase are partnering to help laboratories unlock the full potential of their clinical data.
By connecting Techcyte Fusion® with Biobase’s AI-driven data discovery platform, labs can securely participate in research and commercial collaborations using de-identified pathology data and samples, while maintaining full control over access and participation.
The goal: help labs expand the value of digital pathology and create new opportunities from existing clinical data.
Read more about it→ https://hubs.ly/Q04fSBWz0
SOURCE: LinkedIn
